Objective: To assess the economic impact of providing real time continuous glucose monitoring (CGM) for people with type 1 diabetes (T1D) and impaired awareness of hypoglycaemia (IAH) within North West (NW) London clinical commissioning groups (CCGs). Methods: The eligible population for CGM and inputs for the economic budget impact model developed were derived from published data. The model includes cost of CGM; cost savings associated with lower hypoglycaemia related hospital admissions, accidents and emergency visits; self-monitoring of blood glucose (SMBG) strip usage; and glycated haemoglobin (HbA1c) reduction-related avoided complications and insulin pump use. Results: The cost of CGM for T1D-IAH (n=3,036) in the first year is £10,770,671 and in the fourth year is £11,329,095. The combined cost off-sets related to reduced hypoglycaemia admissions, SMBG strip usage and complications are £8,116,912 and £8,741,026 in years one and four, respectively. The net budget impact within the NW London CCGs is £2,653,760; £2,588,068 in years one and four respectively. Conclusions: Introduction of CGM for T1D-IAH patients will have a minimal budget impact on NW London CCGs, driven by cost of CGM and offsets from lower hypoglycaemia-related costs, reduced SMBG strip usage, avoided HbA1c-related complications and lower insulin pump use.
Continuous glucose monitoring, economics,
type 1 diabetes, clinical commissioning group
Shraddha Chaugule is an employee
of Dexcom, Inc. Brigitte Klinkenbijl is an employee
of Dexcom, Inc. and owns stock in the company.
Claudia Graham is an employee of Dexcom, Inc.
and owns stock in the company. Nick Oliver has
nothing to declare in relation to this article.
Brigitte Klinkenbijl, International
Access, Dexcom Operating Limited, Tanfield, Edinburgh,
EH3 5DA, Scotland, UK. E: firstname.lastname@example.org
The publication of this article was
supported by Dexcom, Inc. The views and opinions
expressed are those of the authors and do not
necessarily reflect those of Dexcom, Inc.
This article is published under the
Creative Commons Attribution Noncommercial License,
which permits any non-commercial use, distribution,
adaptation and reproduction provided the original
author(s) and source are given appropriate credit.
Share this Article
Related Content In Diabetes
Insights into the Feasibility and Acceptability of a Mobile Insulin Titration Application in Clinical Practice and Its Effects on Diabetes Outcomes
touchREVIEWS in Endocrinology. 2024;20(1): Online ahead of journal publication
Despite the increasing body of knowledge of treatment strategies for diabetes, many patients with type 2 diabetes mellitus (T2DM) are still in a persistent state of poor glycaemia.1,2 In clinical practice, achieving optimal glycaemic targets is challenging; the reasons are complex, as both patient- and healthcare provider (HCP)-related factors can play a significant role.3,4 When lifestyle […]
Bexagliflozin as an Adjunct Therapy to Diet and Exercise to Improve Glycaemic Control in Adults with Type 2 Diabetes
touchREVIEWS in Endocrinology. 2024;20(1):Online ahead of journal publication
Type 2 diabetes (T2D) is one of the most common chronic noncommunicable diseases, its incidence is exponentially increasing and is one of the leading causes of morbidity and mortality worldwide.1 As of 2021, T2D ranked among the top causes of premature death and was responsible for more than 6.5 million deaths.2 Currently, approximately 537 million people (over […]
Foreword: touchREVIEWS in Endocrinology 19.2
Welcome to the latest edition of touchREVIEWS in Endocrinology. In this issue we feature a range of articles to keep you up to date with the latest discussions and developments in the field of medical endocrinology. We start with an expert interview from the Founder and CEO of the Global Liver Institute, Donna Cryer, who […]